Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results

Bristol Myers Squibb & Co BMY reported better-than-expected earnings for its third quarter.

Bristol Myers Squibb said revenues came in at $10.966 billion, due to lower sales of Revlimid, partially offset by in-line products and its new product portfolio. Analysts were expecting sales of $10.965 billion. Adjusted EPS rose 1% year-over-year to $2.00, beating the consensus of $1.76.

Bristol Myers Squibb shares fell 3.8% to trade at $50.94 on Friday.

These analysts made changes to their price targets on Bristol Myers Squibb following earnings announcement.

  • HSBC cut the price target on Bristol Myers Squibb from $55 to $53. HSBC analyst Rajesh Kumar upgraded the stock from Reduce to Hold.
  • Barclays slashed the price target on Bristol Myers Squibb from $60 to $51. Barclays analyst Carter Gould maintained an Equal-Weight rating.
  • Morgan Stanley lowered the price target on Bristol Myers Squibb from $56 to $50. Morgan Stanley analyst Terence Flynn maintained an Underweight rating.
  • William Blair analyst Matt Phipps, meanwhile, downgraded Bristol-Myers from Outperform to Market Perform.
  • BMO Capital analyst Evan Seigerman downgraded the stock from Outperform to Market Perform.

Also Check This Out: Top 4 Industrial Stocks That May Plunge In Q4

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: EarningsNewsPrice TargetIntraday UpdateMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!